Corbevax: Discussions underway for WHO approval for Corbevax Covid-19 vaccine, says developer India News – Times of India

Houston: Corbewax, a ‘recombinant protein sub-unit’ vaccine developed by Texas-based vaccine developers was recently given emergency approval by the Indian government and will be manufactured by Hyderabad-based company Biological E, one of the world’s largest vaccine manufacturers. is one.
This “old school” coronavirus vaccine was developed by Prof. Peter Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, with his longtime collaborator Maria Elena Botajic,
Scientific pair is already in discussion with World Health Organization (WHO) for vaccine approval to vaccinate the developing and under-vaccinated world.
“Organic E has started discussions with the World Health Organisation. We have been in some discussions as well. We want to make it available as widely as possible, especially to people living in poverty,” Prof Hotez told ANI in a statement. Told in virtual interview. ,
Hotez stressed how Corbevax “checks many boxes” for global health and is easy to scale, it has a good track record of safety, simple refrigeration and more.
The vaccine developer continued, “It’s actually an almost ideal target product profile. So we’re finding out with the World Health Organization what they need for a pre-qualification or emergency use list. I think those discussions are ongoing.” ”
Corbevax – has been granted emergency use authorization from the Drug Controller General of India (DCGI). It is expected to debut in India and then be made available in other low-wax countries.
The Indian government has already ordered 30 crore doses of the vaccine. BioE plans to produce 100 million or more doses per month starting in February.
About 150 million doses have already been produced and are ready to be rolled out. In addition, Bioi plans to deliver more than a billion additional doses to other countries.
“Corbevax is an old-school vaccine and is made through microbial fermentation in yeast, a process similar to the one used to produce the recombinant hepatitis B vaccine,” explains Hotez. The opinion of experts that protein-based COVID-19 vaccines could be game- changing in the coming days.
“I think the advantage of mRNA technology is that you can make a piece of mRNA very quickly. So you can get into the mRNA loss population quickly and like any new technology, there’s so much knowledge about how to make it.” No. Billions of doses immediately,” Hotez says.
“A balanced portfolio with a vaccine like ours that takes a little longer to make because it takes longer to make protein than mRNA. But in the end, you’ll make it because you can grow it to the world because it’s local. form,” says Hotez.
Touted as a low-cost yet highly effective vaccine, Hotez and his team aim to achieve global vaccine equity and eliminate vaccine hesitation and denial.
“Delta [variant] Earlier this year it emerged from a non-vaccinated population in India and look at Omicron, it emerged from a non-vaccinated population out of southern Africa. therefore mother nature Telling us what He has in store for us. As long as we refuse to vaccinate Africa, Asia and Latin America, she will continue to throw variants around the world and it is surprising that people do not understand that they somehow think that if they are in Europe and North America. Let’s vaccinate our population in the U.S. It looks like it’s good enough, and it’s not,” Prof Hotez insisted.
Hotez and Bottazzi won’t get a penny from this individually and Corbevax is being shared patent-free.
“It’s been my dream to use science to help humanity,” Hotez said. Professor Hotez told ANI, “It brings things full circle in a way that we are able to contribute where we don’t try to make money, we want to help the world.”
For some vaccine developers, the pandemic resulted in billions of dollars in profits in addition to receiving massive amounts of public funding to produce the vaccines, with developers Hotez and Botazzi raising $7 million mostly from private investors and developing Corbevax with minimal help from the US government. Did.
“The problem was an upstream failure. There was so much reliance on new technologies that I sometimes call “shiny new toys,” Hotez said.
“The problem was that we never got support. I mean, it wasn’t that we never got real support from the US government or the G7 countries. So it was a very dark time for me personally, at the start of this pandemic. , said Hotez.
When asked about the vaccine’s efficacy and how much impact the vaccine will have, Hotez said the DCGI’s approval is a strong indication that the vaccine is safe and effective. “They (DCGI) are not going to let any vaccine go out the door unless it is both safe and effective. So, I think you would have a very good option.”
In India, where only 40 percent of the country’s 1.38 billion people are fully vaccinated, Hotez says there’s an urgent need to get everyone vaccinated “whatever your doctor or healthcare provider does to that vaccine.” Recommends to get.”
Corbevax has completed two Phase III clinical trials involving over 3000 subjects between the ages of 18 and 80 years at 33 study sites across India. According to the BioE, the vaccine was found to be safe, tolerable and immunogenic.
After administering over 100 crore doses to adults, India is slowly shifting its focus towards immunizing children against coronavirus. Hotez acknowledged that Corbevax could make a difference.
For now, the vaccine is approved for 18 years and older, but Hotez is confident that Corbevax could be used in pediatric health care and even as a booster going forward.